Research: Weight loss drugs can also reduce the risk of Alzheimer's.
Recently, a large-scale study on popular weight loss drugs showed that patients using GLP-1 medications (such as Novo-Nordisk A/S's Ozempic and Wegovy, and Eli Lilly and Co's Mounjaro) had a 12% reduced risk of developing Alzheimer's disease, but there was an increase in the risk of arthritis, kidney, and pancreatic diseases.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
LVMH Is Once Again the Largest Company in Europe by Market Cap
Why Did Novo Nordisk (NVO) Go Down on Friday?
Trending Stocks as Wall Street Bounces Back With Strong Week
Top Gap Ups and Downs on Friday: NVO, UBS, IBN and More
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Money Thrill OP : Successful Weight Loss Study Cercle Finance (01/17/2025)(CercleFinance.com) - Novo Nordisk reports that its Phase 3b STEP UP study has met its primary endpoint, demonstrating statistically significant and superior weight loss at week 72 with subcutaneous semaglutide 7.2 mg compared to placebo. From an average baseline body weight of 113 kg, those treated with semaglutide 7.2 mg achieved 20.7% greater weight loss, compared to reductions of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. Additionally, 33.2% of those who received semaglutide 7.2 mg saw weight loss of 25% or more, compared to 1